• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Assessing statins use in a real-world primary care digital strategy: a cross-sectional analysis of a population-wide digital health approach
Lancet Reg Health Am. 2023 Jun 22;23:100534. doi: 10.1016/j.lana.2023.100534. eCollection 2023 Jul.ABSTRACTBACKGROUND: The digitization of the primary care system provides an opportunity to evaluate the current use of statins in secondary prevention populations (myocardial infarction or stroke).METHODS: We conducted a cross-sectional study (ClinicalTrials.gov, NCT05285085), analysing anonymised data routinely collected by community health workers (CHW) in Brazil between May 2016 and September 2021 to assess the proportion of self-reported statins use and associated factors.FINDINGS: From the 2,133,900 individuals on the da...
Source: Atherosclerosis - July 27, 2023 Category: Cardiology Authors: M Julia Machline-Carrion Alysson Nathan Girotto Josu é Nieri Pedro Marton Pereira Frederico Monfardini Francisco Forestiero Priscila Raupp Fabiana Roveda Karla Santo Ot ávio Berwanger Raul D Santos Source Type: research

Pentraxin 3 in Cardiovascular Disease
Giuseppe Ristagno1*, Francesca Fumagalli1, Barbara Bottazzi2, Alberto Mantovani2,3,4, Davide Olivari1, Deborah Novelli1 and Roberto Latini1 1Department of Cardiovascular Research, Mario Negri Institute for Pharmacological Research IRCCS, Milan, Italy 2Humanitas Clinical and Research Center-IRCCS, Milan, Italy 3Humanitas University, Milan, Italy 4The William Harvey Research Institute, Queen Mary University of London, London, United Kingdom The long pentraxin PTX3 is a member of the pentraxin family produced locally by stromal and myeloid cells in response to proinflammatory signals and microbial moieties. The p...
Source: Frontiers in Immunology - April 16, 2019 Category: Allergy & Immunology Source Type: research

Sex-specific relevance of diabetes to occlusive vascular and other mortality: a collaborative meta-analysis of individual data from 980  793 adults from 68 prospective studies
Publication date: Available online 8 May 2018 Source:The Lancet Diabetes & Endocrinology Author(s): Prospective Studies Collaboration and Asia Pacific Cohort Studies CollaborationLGnatiucWGHerringtonJHalseyJTuomilehtoXFangHCKimDDe BacquerAJDobsonMHCriquiDRJacobsJrDALeonSAEPetersHUeshimaPSherlikerRPetoRCollinsRRHuxleyJREmbersonMWoodwardSLewingtonNAokiHArimaEArnesenAAromaaGAssmannDLBachmanCBaigentHBartholomewABenetosCBengtssonDBennettCBjörkelundHBlackburnKBonaaEBoyleRBroadhurstJCarstensenLChamblessZChenSKChewRClarkeCCoxJDCurbRD'AgostinoCDateGDavey SmithGDe BackerSSDhaliwalXFDuanPDucimetiereSDuffyHEliassenPElwoodJEm...
Source: The Lancet Diabetes and Endocrinology - May 9, 2018 Category: Endocrinology Source Type: research

Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial
Publication date: Available online 15 September 2017 Source:The Lancet Diabetes & Endocrinology Author(s): Marc S Sabatine, Lawrence A Leiter, Stephen D Wiviott, Robert P Giugliano, Prakash Deedwania, Gaetano M De Ferrari, Sabina A Murphy, Julia F Kuder, Ioanna Gouni-Berthold, Basil S Lewis, Yehuda Handelsman, Armando Lira Pineda, Narimon Honarpour, Anthony C Keech, Peter S Sever, Terje R Pedersen Background The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab reduced LDL cholesterol and cardiovascular events in the FOURIER trial. In this prespecified analysis of FOURIER, we investigated ...
Source: The Lancet Diabetes and Endocrinology - September 16, 2017 Category: Endocrinology Source Type: research

Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials
Publication date: Available online 29 July 2016 Source:The Lancet Diabetes & Endocrinology Author(s): Cholesterol Treatment Trialists' (CTT) Collaboration Background Statin therapy is effective for the prevention of coronary heart disease and stroke in patients with mild-to-moderate chronic kidney disease, but its effects in individuals with more advanced disease, particularly those undergoing dialysis, are uncertain. Methods We did a meta-analysis of individual participant data from 28 trials (n=183 419), examining effects of statin-based therapy on major vascular events (major coronary event [non-fatal myoca...
Source: The Lancet Diabetes and Endocrinology - July 28, 2016 Category: Endocrinology Source Type: research

Why You Should Avoid Statins
At my anti-aging clinic, I continue to wage war against what I call the “medical-industrial complex.” And I do it for one reason only – I care more about my patients than I do about profits. Big Pharma clearly takes the opposite view. And now it seems these pharmaceutical behemoths won’t be happy until every man, woman and child is popping anti-cholesterol pills. Researchers at Duke University recently issued a report recommending that even children and people as young as 30 should be on statins, if they have just slightly elevated cholesterol levels.1 And why wouldn’t researchers at Duke recommen...
Source: Al Sears, MD Natural Remedies - February 3, 2015 Category: Complementary Medicine Authors: Dr. Al Sears Tags: Heart Health Source Type: news